Share: APPROVAL ALLOWS RESOLUTE 2.0 TEST KIT TO BE USED WITH A VARIETY OF TESTING METHODS – INCLUDING DEEP-THROAT SALIVA, OROPHARYNGEAL/MIDDLE TURBINATE AND NASOPHARYNGEAL TEST SWABS RESOLUTE 2.0 WILL BE USED AT SINGAPORE CHANGI AIRPORT WITH THE NEW ON-SITE ADDITION OF A COVID-19 TESTING LAB IN 2021. Advanced MedTech Holdings (AMTH), a global medical technology leader headquartered in Singapore, announced today that the RESOLUTE 2.0 test kit has become the first RT-PCR COVID-19 test to be authorised by Singapore's Health Sciences Authority (HSA) for deep-throat saliva (DTS) SARS-CoV-2 testing. The clinical performance of DTS is supported by clinical studies involving the Diagnostics Development (DxD) Hub hosted by the Agency for Science, Technology and Research (A*STAR); Temasek Foundation; Changi General Hospital (CGH); DSO National Laboratories (DSO); and Woodlands Health Campus (WHC). The tests conducted on DTS specimens were able to accurately identify all the known positive cases in the clinical studies.